Guggenheim starts DBV Technologies at Buy on peanut allergy market potential

As previously reported, Guggenheim initiated coverage of DBV Technologies (DBVT) with a Buy rating and $35 price target citing a positive view of the company’s unique epicutaneous immunotherapy approach to combat peanut allergy in the pediatric population and the potential to capitalize on this “large untapped” peanut allergy market. Palforzia, marketed by Stallergenes Greer, is currently the only approved immunotherapy in peanut allergy, but it comes with noteworthy disadvantages, and DBV aims to revitalize the peanut allergy immunotherapy space by introducing a more convenient, safe, and effective alternative to an oral therapy with its Viaskin peanut patch, the analyst tells investors.